Legend Biotech (LEGN) Q4 2025 Earnings Transcript

CARVYKTI net trade sales were $555M in Q4 (up 66% YoY) driving Legend’s total revenue of $306M (+64% YoY) with a 61% gross margin and adjusted net income of $2.5M versus a $59M adjusted loss a year ago. Operating margin improved to negative 6% (operating loss ~-$20M), cash stood at $949M, and manufacturing now supports 10,000 annual doses with plans to expand to up to 20,000 and reported 97–99% success rates. Management expects ~50% CARVYKTI top-line growth in 2026, sequential quarterly growth through the year, and company-wide profitability in 2026, reinforcing commercialization and capacity execution. Key risks remain competitive dynamics, regulatory/readthroughs for MRD/in‑vivo programs and execution of capacity expansion and BD initiatives.

Analysis

Legend’s recent cadence crystallizes a path from launch execution to scale, but the real alpha will come from three interlocking mechanisms: durable clinical differentiation, lower per-dose landed cost as more treatments shift outpatient, and payer willingness to accept front-loaded one-time payments versus chronic bispecific regimens. If outpatient share continues to rise, hospital capture of ancillary revenue falls while unit economics for the manufacturer improve — this creates a multi-quarter margin kicker that is underappreciated by consensus modeling.

Second-order supply dynamics matter more than headline capacity. Automation, process yield improvements, and the operational learning curve create convex upside to delivered capacity versus linear CapEx plans; conversely, incremental late-line manufacturing dropouts (and any unexpected regulatory hold on in-vivo approaches) are asymmetric downside events because they compress available supply precisely when earlier-line adoption is accelerating. Expect volatility around any manufacturing or regulatory readouts rather than smooth linear growth.

Regulatory and payer sequencing are the largest non-technical risks. Payers will test sequencing economics (one-time CAR-T vs repeated bispecific therapy) by carving narrow step edits or outcome-based contracts; failure to secure broad, precedent-setting value-based contracts in key commercial payers could materially delay uptake in earlier lines. Short-term readouts from next-gen/in-vivo assets are high-information but binary: positive translational signals would compress TAM timelines (years), while safety/regulatory setbacks would push adoption curves out and hand share to bispecific incumbents.

Key Decisions for Investors

• Long LEGN equity with defined hedge: Buy LEGN stock size = tactical exposure (5% of target biotech allocation) and protect downside with LEGN Jan-2027 puts ~25% OTM (or equivalent collar). Rationale: asymmetric upside to successful mid-cycle clinical and capacity catalysts; hedge limits downside from regulator/payer shocks. Timeframe: 6–12 months. Risk/Reward: cost of hedge caps loss to ~20–30% while upside remains multiples if adoption and in-vivo readouts land.
• Buy a leveraged call spread on LEGN (12-month): purchase LEGN Jan-2027 call and sell a higher-strike Jan-2027 call to finance premium (target net debit ~5–10% of notional). Rationale: concentrates exposure to commercialization and data catalysts with capped risk. Timeframe: 9–15 months. Risk/Reward: limited downside (premium paid), potential 3–5x return if catalysts beat and market re-rates.
• Hedge macro/competitive sequencing risk with JNJ LEAPS: buy JNJ 2027 LEAPS as defensive complement (smaller notional than LEGN exposure). Rationale: partner benefits from scale and can blunt distribution/regulatory disruptions; this reduces portfolio idiosyncratic execution risk. Timeframe: 12–24 months. Risk/Reward: conservative upside, lower volatility, protects vs partner-led commercialization shocks.
• Event-driven short candidate (selective small-cap CAR-T or bispecific vendor): identify a small-cap competitor lacking manufacturing depth and short into data windows and capacity announcements (avoid broad sector shorts). Rationale: successful scale by a leader compresses share for under-capitalized peers and exposes those names to binary failure risk. Timeframe: 3–12 months. Risk/Reward: high-risk, high-reward — size modestly and use event stops around readouts.